Tryp Therapeutics Inc.
TRYPF · OTC
8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,356 | $2,964 | $890 | $8 |
| G&A Expenses | $2,368 | $4,400 | $4,414 | $387 |
| SG&A Expenses | $2,368 | $4,400 | $6,398 | $414 |
| Sales & Mktg Exp. | $0 | $0 | $1,985 | $28 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,724 | $7,364 | $7,288 | $423 |
| Operating Income | -$4,702 | -$7,230 | -$6,311 | -$423 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$543 | -$265 | -$967 | $0 |
| Pre-Tax Income | -$5,267 | -$7,495 | -$8,255 | -$423 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,267 | -$7,495 | -$8,255 | -$423 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.096 | -0.12 | -0.011 |
| % Growth | 43.1% | 20% | -990.9% | – |
| EPS Diluted | -0.055 | -0.096 | -0.12 | -0.011 |
| Weighted Avg Shares Out | 96,419 | 78,065 | 66,669 | 38,392 |
| Weighted Avg Shares Out Dil | 96,419 | 78,065 | 66,669 | 38,392 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $11 | $0 |
| Interest Expense | $522 | $0 | $0 | $0 |
| Depreciation & Amortization | $168 | $228 | $237 | $206 |
| EBITDA | -$4,702 | -$7,230 | -$6,311 | $0 |
| % Margin | – | – | – | – |